244 Chapter 8 References 1. Arnold L, Enders J, Thomas SM. Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers (Basel) 2017;9. 2. De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci 2008;13:2516-26. 3. Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S. Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Crit Rev Oncol Hematol 2017;111:39-51. 4. Brusevold IJ, Soland TM, Khuu C, Christoffersen T, Bryne M. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci 2010;118:342-9. 5. Chen YS, Wang JT, Chang YF, Liu BY, Wang YP, Sun A, et al. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004;33:209-17. 6. Choe JY, Yun JY, Nam SJ, Kim JE. Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. Korean J Pathol 2012;46:515-22. 7. Fiedler M, Weber F, Hautmann MG, Haubner F, Reichert TE, Klingelhoffer C, et al. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. Clin Oral Investig 2018;22:189-200. 8. Freudlsperger C, Alexander D, Reinert S, Hoffmann J. Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med 2010;1:69-72. 9. Khan M, Khaznadar SS, Routila J, Ventela S, Schmid E, Gebhart B, et al. Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. Head Neck 2020;42:625-35. 10. Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010;32:1655-64. 11. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009;15:3740-50. 12. Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, et al. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One 2014;9:e84319. 13. Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, et al. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol 2012;48:1114-9. 14. Lo Muzio L, Leonardi R, Mignogna MD, Pannone G, Rubini C, Pieramici T, et al. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res 2004;24:1063-9. 15. Luttich L, Besso MJ, Heiden S, Koi L, Baumann M, Krause M, et al. Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. Cancers (Basel) 2021;13. 16. Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, et al. Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther 2020;19:614-26. 17. Szturz P, Budikova M, Vermorken JB, Horova I, Gal B, Raymond E, et al. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. Oral Oncol 2017;74:68-76. 18. Vsiansky V, Gumulec J, Raudenska M, Masarik M. Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis. Sci Rep 2018;8:10370.
RkJQdWJsaXNoZXIy MTk4NDMw